发明授权
US07232563B2 Hybrid interferon/interferon tau proteins, compositions and methods of use
失效
混合干扰素/干扰素tau蛋白,组合物和使用方法
- 专利标题: Hybrid interferon/interferon tau proteins, compositions and methods of use
- 专利标题(中): 混合干扰素/干扰素tau蛋白,组合物和使用方法
-
申请号: US10218338申请日: 2002-08-12
-
公开(公告)号: US07232563B2公开(公告)日: 2007-06-19
- 发明人: Lorelie H. Villarete , Jackeline Campos , Wayne Li
- 申请人: Lorelie H. Villarete , Jackeline Campos , Wayne Li
- 申请人地址: US CA Alameda
- 专利权人: Pepgen Corporation
- 当前专利权人: Pepgen Corporation
- 当前专利权人地址: US CA Alameda
- 代理机构: Perkins Coie LLP
- 代理商 Brian S. Boyer
- 主分类号: A61K38/21
- IPC分类号: A61K38/21 ; A61K39/00 ; C07K14/00
摘要:
The present invention relates to hybrid interferon fusion proteins formed of an interferon-α protein where the C-terminal region of the interferon-α protein is replaced by a C-terminal region of interferon-τ. Also described are nucleic acid sequences encoding the interferon fusion proteins, expression vectors containing such sequences, and therapeutic applications of the interferon fusion proteins. The therapeutic applications include antiviral, anticellular proliferation, and anti-inflammatory applications. One advantage of the interferon fusion polypeptides of the present invention is that they have lower cytotoxic side effects when used to treat cells.
公开/授权文献
信息查询
IPC分类: